This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2929v1 69/6/2559    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ma, O. Articles by Donehower, L. A. Search for Related Content PubMed PubMed Citation Articles by Ma, O. Articles by Donehower, L. A.

MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression

¹ Department of Molecular Virology and Microbiology, ² Dan L. Duncan Cancer Center, ³ Department of Molecular and Human Genetics, ⁴ Program in Cell and Molecular Biology, ⁵ Texas Children's Cancer Center, Department of Pediatrics, ⁶ Center for Comparative Medicine and Department of Pathology, and ⁷ Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas and ⁸ Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Requests for reprints: Lawrence A. Donehower, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030. Phone: 713-798-3594; Fax: 713-798-3490; E-mail: larryd{at}bcm.tmc.edu.

Key Words: p53 • osteosarcoma • MMP13 • Birc2 • Birc3

Osteosarcoma is the primary malignant cancer of bone and particularly affects adolescents and young adults, causing debilitation and sometimes death. As a model for human osteosarcoma, we have been studying p53^+/– mice, which develop osteosarcoma at high frequency. To discover genes that cooperate with p53 deficiency in osteosarcoma formation, we have integrated array comparative genomic hybridization, microarray expression analyses in mouse and human osteosarcomas, and functional assays. In this study, we found seven frequent regions of copy number gain and loss in the mouse p53^+/– osteosarcomas but have focused on a recurrent amplification event on mouse chromosome 9A1. This amplicon is syntenic with a similar chromosome 11q22 amplicon identified in several human tumor types. Three genes on this amplicon, the matrix metalloproteinase gene MMP13 and the antiapoptotic genes Birc2 (cIAP1) and Birc3 (cIAP2), show elevated expression in mouse and human osteosarcomas. We developed a functional assay using clonal osteosarcoma cell lines transduced with lentiviral short hairpin RNA vectors to show that down-regulation of MMP13, Birc2, or Birc3 resulted in reduced tumor growth when transplanted into immunodeficient recipient mice. These experiments revealed that high MMP13 expression enhances osteosarcoma cell survival and that Birc2 and Birc3 also enhance cell survival but only in osteosarcoma cells with the chromosome 9A1 amplicon. We conclude that the antiapoptotic genes Birc2 and Birc3 are potential oncogenic drivers in the chromosome 9A1 amplicon. [Cancer Res 2009;69(6):2559–67